CIRCLE-seq

CIRCLE-seq identifies genome-wide off-target cleavage sites induced by the CRISPR-Cas9 system using an in vitro circularization assay coupled to next-generation sequencing for specificity assessment.

Key Features:

• High sensitivity and efficiency: Detects genome-wide CRISPR-Cas9 off-target cleavage with high sensitivity, enabling identification of low-frequency off-target events.
• In vitro approach: Operates entirely in vitro via DNA circularization, avoiding live-cell requirements and reducing sources of experimental variability.
• Next-generation sequencing compatibility: Leverages next-generation sequencing technologies to read and report cleavage sites.
• Independence from reference genomes: Can be applied without reliance on reference genome sequences.
• SNP-associated detection and personalized specificity: Detects off-target sites associated with cell-type-specific single-nucleotide polymorphisms (SNPs), enabling personalized specificity profiles.
• Performance relative to other methods: Exhibits higher sensitivity than cell-based or biochemical methods for detecting off-target mutations.

Scientific Applications:

• Therapeutic development: Provides comprehensive off-target assessment to inform safety and specificity optimization of CRISPR-Cas9 therapeutics.
• Genomic research: Enables genome-wide investigation of unintended CRISPR-Cas9–induced genetic modifications.
• Personalized medicine: Supports generation of individualized specificity profiles by detecting SNP-associated off-target events.

Methodology:

The description specifies an in vitro circularization-based assay followed by next-generation sequencing; computational analysis steps were not specified.